Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
The BURST CME™ format is an online, on-demand video program designed to deliver concise, modular education. In these modules, Pam Taub, MD; and Payal Kohli, MD, review the relationship between lipoprotein(a) or Lp(a) and atherosclerotic cardiovascular disease (ASCVD), proper Lp(a) testing, selecting appropriate patients for testing, as well as current and emerging therapies to reduce the risk of ASCVD in patients with elevated Lp(a). A case study will be reviewed to illustrate how patients with elevated Lp(a) can be effectively managed, with expert faculty providing clinical pearls along the way.
Target Audience
This educational activity is directed toward cardiologists, lipidologists, primary care providers, NPs, PAs, RNs, and other health care professionals involved in the management of ASCVD and its risk-associated factors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the role of Lp(a) in the atherosclerotic processes that lead to ASCVD
- Outline which patient populations should be screened for elevated Lp(a) as a step toward reducing their risk for ASCVD
- Explain the progressive impact of elevated LDL-C levels on the risk of ASCVD onset
- Evaluate safety and efficacy data of new and emerging lipid-lowering therapies for ASCVD risk reduction
- Implement tailored treatment plans for patients who have or are at risk for ASCVD due to persistently elevated levels of LDL-C and/or Lp(a)
Pam R. Taub, MD, FACC, FASPC
Step Family Director's Endowed Chair
Director of Preventive Cardiology
Director of Step Family Cardiovascular Rehabilitation and Wellness
Center
Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amarin, Amgen, Bayer, Boehringer Ingelheim, Cleerly, Edwards, Esperion, Jazz, Lexicon, Lilly, Medtronic, Novartis, Novo Nordisk, Roche. Grant/Research Funding: Amsterdam, AstraZeneca, CSL Behring, Dexcom,, Merck
Payal Kohli, MD, FACC
Associate Adjunct Professor in Cardiology, Department of Medicine
Johns Hopkins University and Duke University
Founder and Medical Director, Cherry Creek Heart
Aurora, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: 2nd.MD, Agepha Pharma, Amarin, Amgen, Arthritis Foundation, Bayer HealthCare, Biofourmis, BioPharm Communications Media Division, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, CardioCare Medical Education, Clinical Care Options, Eli Lilly and Company, Engage Health, Esperion, Family Heart Foundation, ForMedics, HeartFlow, HealthyWomen, Idorsia, IMRE Health, Included Health, Lexicon Pharmaceuticals, MedLive, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Rochester Regional Health, Stratafluence, Verve Therapeutics, Vindico Medical Education, Viz.ai, VuMedi, Women As One, WomenHeart, ZOLL Medical ; Grant/Research Funding: BioPharm Communications Media Division, Clinical Care Options, Esperion, Family Heart Foundation, ForMedics, HealthyWomen, Idorsia, IMRE Health, Lexicon Pharmaceuticals, Rochester Regional Health, Stratafluence, Verve Therapeutics, Vindico Medical Education, Viz.ai, VuMedi, Women As One, WomenHeart ; Executive Role: Cherry Creek Heart, medical director; Other: 9News/Tegna, medical correspondent; Medical Center of Aurora, medical staff privileges; CME fees: American College of Cardiology, AngioInsight
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here